We embrace the challenge in science

At Dompé, we are deeply committed to partnering with the scientific community. Our goal is to improve the lives of patients living with challenging conditions.

Latest News

We use our 130 years of experience and expertise to turn transformative breakthroughs into treatments

Unafraid to take risks in our R&D, we face each challenge with the determination to deliver new drugs. Our passion for making a meaningful difference in patients’ lives drives our people.

Science

Taking steps to positively impact people’s lives means further expanding our understanding of science and pursuing research and development in new and unexpected areas. With our expertise dating back over 130 years, we know what it takes to create safe, effective drugs even from the most complex molecules.

Nerve Growth Factor

Following several years of research, our committed team of scientists developed cenegermin-bkbj, a recombinant human nerve growth factor (rhNGF). 

Find out more

Exscalate

The most advanced intelligent supercomputing platform for drug screening, and the largest enumerated chemical library in the world for preclinical and clinical candidate identification. 

Find out more

Publications

Working closely with our partnered centres and universities, our researchers contribute to the progress of Life Sciences' knowledge.

Find out more

Pipeline

With our research and development pipeline, we target some of the highest-needing therapeutic areas.

Find out more

Therapeutic areas

Our hunger to keep progressing, and to deliver what patients need from science, keeps us focused on what matters. This approach allows us to develop innovative treatments for people who need them across ophthalmology and beyond.

Manufacturing site

Our production hub in L’Aquila, Italy, is the manufacturing heart of Dompé and where we produce most of our products. Our small molecule production plant is focused on everyday over-the-counter drugs, while our specialized biotech production plant is dedicated to producing our treatment in ophthalmics.

"We have redefined our study areas as platforms based on the biological mechanisms to be investigated. For example, in the field of neuronal growth, we are working on neurotrophins, in immunology on diseases such as juvenile diabetes and we are active in pain, Covid and new approaches to drug discovery"

Nathalie Dompé

Co-Ceo Dompé farmaceutici and Vice President of Business Development Dompé US.